Wolff-Parkinson-White (WPW) Syndrome — Causes, ECG and Treatment

Louis Wolff published an article in 1930 that described 11 patients who had episodes of tachycardia with characteristic ECG findings (ECG pattern showed bundle branch block and a shortened PR interval). In 1943, the anatomical accessory pathway of conducting tissue was described and showed that this pathway bypassed the atroventricular conduction system. This article discusses the definition, pathophysiology, clinical manifestations, diagnosis, and treatment of Wolff-Parkinson-White Syndrome.

Definition

Wolff-Parkinson-White (WPW) syndrome is defined as tachyarrhythmia in which attacks of tachycardia occur in a patient due to the presence of an abnormal accessory pathway in the heart, which bypasses the conduction, fully or partially, via the atroventricular (AV) node to the ventricles. The prognosis and long-term outcome of WPW syndrome are very good, especially if treatment aims to...
eliminate the abnormal accessory pathway.

**Epidemiology**

The prevalence of WPW syndrome and pattern is **less than 1% of the population** with the WPW pattern being 100 times more common than WPW syndrome. The difference between both presentations will be discussed later in this article.

**Pathophysiology**

First, it is important to understand the normal conducting pathway of the heart, and how the impulses spread uniformly throughout the heart. Normally, **the atria and ventricles are electrically isolated, where the discharged electrical impulses move from the SA node in the right atrium to the ventricles via the AV node and His-Purkinje system.**

Patients with the pre-excitation syndrome have an anatomical accessory pathway that directly conducts impulses from the atria to the ventricles, bypassing the AV node of the heart and conducting impulses faster than the AV node without its characteristic delaying property. This results in a short PR interval seen on ECG. This accessory pathway is congenital in origin and results from the failure of resorption of the myocardial syncytium at the annulus fibrosis during fetal development.

- About 75% of the accessory pathway can conduct impulses in both directions (anterograde and retrograde) between the atrium and ventricle.
- About 35% of the accessory pathway is only able to conduct the impulses in a retrograde fashion from the ventricle to the atrium – the so-called ‘concealed’ accessory pathways (most of them are left-sided, which does not create a delta wave and the WPW pattern on ECG, but is still able to support reentrant tachycardia).
- About 25% of the accessory pathway only conducts impulses in an anterograde manner from the atria to the ventricles.

The mechanism of the unidirectional conduction of impulses along the accessory pathway
in either an **anterograde** or **retrograde** direction remains undetermined.

**Anatomy of accessory atrioventricular pathways**

Based on electrophysiological studies, accessory atrioventricular pathways are located in any place along the AV ring or in the interventricular septum. The most frequently documented locations are:

- 50% → Left lateral
- 30% → Posteroseptal
- 10% → Right anteroseptal
- 10% → Right lateral

**Wolff-Parkinson-White pattern and syndrome**

Patients with an accessory pathway can be described as having either the WPW pattern or WPW syndrome based on the presence or absence of **arrhythmias**.

**Wolff-Parkinson-White pattern**

This term applies to a patient with ECG findings of pre-excitation in the **absence of symptomatic arrhythmias**.

**Wolff-Parkinson-White syndrome**

This term applies to a patient with ECG findings of pre-excitation and **symptomatic arrhythmias**. In either situation, anterograde conduction of impulses, from the atria to the ventricles through an accessory pathway, will result in earlier activation or pre-excitation of part of the ventricles.

**Clinical Manifestations**

The vast majority of patients with WPW pattern are **asymptomatic**, while a small percentage have **arrhythmias** (for example, atrial fibrillation with rapid ventricular response) as a part of the WPW syndrome. Patients with WPW syndrome and developed arrhythmia will present with any of the following manifestations:

- Palpitations
- Lightheadedness and/or dizziness
- Syncope or presyncope
- Chest pain
- Sudden cardiac death

**Arrhythmias associated with Wolff-Parkinson-White**

WPW syndrome can be associated with either:

1. **Tachycardias requiring an accessory pathway for initiation and maintenance**

**Atrioventricular reentrant tachycardia (AVRT):** This occurs when the heart has a circuit that consists of 2 pathways – a normal AV conduction system and the AV
The main feature of the AV accessory pathway is pre-excitation, where the ventricles are activated by the direct activation of the myocardium throughout the accessory pathway. Thus, the ventricles are activated earlier than expected after atrial
depolarization, resulting in:

- **Shortening of the PR interval (< 0.12 seconds)** occurs as a result of rapid AV conduction via the accessory pathway, bypassing the AV node
- **Delta wave**, which arises because the beginning of ventricular depolarization is slowed and the QRS complex upstroke is slurried because of the slowing of the conduction from muscle fiber to another muscle fiber. Slow muscle fiber-to-muscle fiber conduction is noted.
- **Widening of the QRS complex**

---

**Concealed accessory pathways**

As mentioned earlier, in about 35-50% of patients, accessory pathways conduct the impulses in the retrograde direction only from the ventricle to the atrium. In this condition, the accessory pathway manifests only during sustained tachycardia. Concealed accessory pathways can be identified by the time, and by how the atrium is activated during tachycardia:

- **P wave follows ventricular depolarization and a short RP wave interval** can be seen.
- Sometimes accessory pathways conduct the retrograde impulses very slowly, which may result in longer retrograde conduction, developing a **longer RP interval during tachycardia** (long RP tachycardia).

**Therapy**

Patients with WPW syndrome are treated because they either have:

1. Symptomatic arrhythmia
2. Risk of arrhythmia, for example, pre-excited atrial fibrillation, or atrial flutter with a rapid ventricular response

Asymptomatic WPW pattern does not need treatment.
Orthodromic AVRT (tachycardia with a narrow QRS complex)

The antegrade limb (the pathway that conducts impulses to the ventricle) is the AV node and His-Purkinje system, thus, ventricles are not pre-excited.

Acute termination

The immediate treatment of macroreentrant orthodromic tachycardias is similar to that for AVNRT, which aims to alter impulse conduction in the AV node.

- **Maneuvers that increase vagal tone**: Valsalva maneuver and carotid sinus pressure can depress AV nodal function, resulting in AV node block and tachycardia termination
- **IV adenosine and calcium channel blockers**: IV adenosine is the first-line pharmacologic therapy for the termination of tachycardia, followed by IV calcium channel blockers such as verapamil
- **Intravenous procainamide, B-blockers, and digoxin**: They are the second-line treatment for terminating the tachycardia.

Antidromic AVRT (tachycardia with a wide QRS complex)

The antegrade limb is the accessory pathway, thus, ventricles are pre-excited. Treatment should be aimed at preventing rapid ventricular response if the patient manifests with pre-excitation and atrial fibrillation in order to avoid atrial fibrillation.

- **In unstable patients**: Electrical DC cardioversion should be used to rapidly correct the atrial fibrillation.
- **In stable patients**: Procainamide administered at a dose of 15 mg/kg will slow the rapid ventricular response and may correct the atrial fibrillation.

**Note**: Care is necessary when attempting to slow the AV nodal conduction with digoxin or calcium channel blockers because they may result in accelerating conduction over the accessory pathway (accessory pathway) which may result in atrial fibrillation.

Catheter ablation therapy
Catheter ablation therapy appears to be **effective in more than 90% of patients** with WPW syndrome regardless of age. It is indicated in a patient with a history of:

1. Recurrent symptomatic supraventricular tachycardia
2. Incessant supraventricular tachycardia
3. Heart rates > 200/min with supraventricular tachycardia

**Prevention**

Prevention of recurrent supraventricular reentrant tachycardias that are associated with accessory pathways (accessory pathways) is possible with the chronic oral administration of **B-blockers and/or calcium channel blockers (verapamil or diltiazem).**

Patients with atrial fibrillation and rapid ventricular response should receive class IA or IC antiarrhythmic drugs, such as quinidine, flecainide or propafenone, to slow conduction through the accessory pathway and increase its refractory period.

**References**


**Legal Note:** Unless otherwise stated, all rights reserved by Lecturio GmbH. For further legal regulations see our [legal information page](#).